

**Parecoxib (Dynastat<sup>o</sup>)**

**(No. 27/02)**

**Pharmacia**

**Summary of Recommendation**

10 January 2003

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The recommendation is summarised as follows:

**ADVICE**

Parecoxib is not recommended for use within NHS Scotland.

**RECOMMENDATION**

There is no evidence that the parenteral COX-2 selective non-steroidal anti-inflammatory drug (NSAID), parecoxib, is associated with a reduction in clinically significant post-operative haemorrhagic or gastro-intestinal complications compared with the non-selective NSAIDs. Parecoxib is substantially more expensive than non selective NSAIDs and should therefore not replace these drugs.

The license holder has indicated their decision to resubmit in light of additional information.

**D H Lawson**  
**Chairman**